Comparison of the Pharmacokinetics of CT-P13 between Crohn's Disease and Ulcerative Colitis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, E.S. | - |
dc.contributor.author | Kim, S.K. | - |
dc.contributor.author | Park, D.I. | - |
dc.contributor.author | Kim, H.J. | - |
dc.contributor.author | Lee, Y.J. | - |
dc.contributor.author | Koo, J.S. | - |
dc.contributor.author | Kim, E.S. | - |
dc.contributor.author | Yoon, H. | - |
dc.contributor.author | Lee, J.H. | - |
dc.contributor.author | Kim, J.W. | - |
dc.contributor.author | Shin, S.J. | - |
dc.contributor.author | Kim, H.W. | - |
dc.contributor.author | Kim, H.-S. | - |
dc.contributor.author | Park, Y.S. | - |
dc.contributor.author | Kim, Y.S. | - |
dc.contributor.author | Kim, T.O. | - |
dc.contributor.author | Lee, J. | - |
dc.contributor.author | Choi, C.H. | - |
dc.contributor.author | Han, D.S. | - |
dc.contributor.author | Chun, J. | - |
dc.contributor.author | Kim, H.S. | - |
dc.date.accessioned | 2023-11-24T03:01:31Z | - |
dc.date.available | 2023-11-24T03:01:31Z | - |
dc.date.created | 2022-06-09 | - |
dc.date.issued | 2023-07 | - |
dc.identifier.issn | 0192-0790 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/192871 | - |
dc.description.abstract | Background: We aimed to compare trough infliximab levels and the development of antidrug antibody (ADA) for 1 year between Crohn's disease (CD) and ulcerative colitis (UC) patients who were biologic-naive, and to evaluate their impact on clinical outcomes. Methods: This was a prospective, multicenter, observational study. Biologic-naive patients with moderate to severe CD or UC who started CT-P13, an infliximab biosimilar, therapy were enrolled. Trough drug and ADA levels were measured periodically for 1 year after CT-P13 initiation. Results: A total of 267 patients who received CT-P13 treatment were included (CD 168, UC 99). The rates of clinical remission (72% vs. 32.3%,P<0.001) at week 54 were significantly higher in CD than in UC. The median trough drug level (μg/mL) was significantly higher in CD than in UC up to week 14 (week 2, 18.7 vs. 14.7,P<0.001; week 6, 12.5 vs. 8.6,P<0.001; week 14, 3.4 vs. 2.5,P=0.001). The median ADA level (AU/mL) was significantly lower in CD than in UC at week 2 (6.3 vs. 6.5,P=0.046), week 30 (7.9 vs. 11.8,P=0.007), and week 54 (9.3 vs. 12.3,P=0.032). Development of ADA at week 2 [adjusted odds ratio (aOR)=0.15,P=0.026], initial C-reactive protein level (aOR=0.87,P=0.032), and CD over UC (aOR=1.92,P<0.001) were independent predictors of clinical remission at week 54. Conclusion: Infliximab shows more favorable pharmacokinetics, including high drug trough and low ADA levels, in CD than in UC, which might result in better clinical outcomes for 1-year infliximab treatment in CD patients. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Lippincott Williams and Wilkins | - |
dc.title | Comparison of the Pharmacokinetics of CT-P13 between Crohn's Disease and Ulcerative Colitis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Han, D.S. | - |
dc.identifier.doi | 10.1097/MCG.0000000000001715 | - |
dc.identifier.scopusid | 2-s2.0-85129899505 | - |
dc.identifier.wosid | 001009895300010 | - |
dc.identifier.bibliographicCitation | Journal of Clinical Gastroenterology, v.57, no.6, pp.601 - 609 | - |
dc.relation.isPartOf | Journal of Clinical Gastroenterology | - |
dc.citation.title | Journal of Clinical Gastroenterology | - |
dc.citation.volume | 57 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 601 | - |
dc.citation.endPage | 609 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | INFLAMMATORY-BOWEL-DISEASE | - |
dc.subject.keywordPlus | TUMOR-NECROSIS-FACTOR | - |
dc.subject.keywordPlus | SERUM INFLIXIMAB | - |
dc.subject.keywordPlus | ANTIDRUG ANTIBODIES | - |
dc.subject.keywordPlus | MAINTENANCE THERAPY | - |
dc.subject.keywordPlus | INDUCTION THERAPY | - |
dc.subject.keywordPlus | TNF-ALPHA | - |
dc.subject.keywordPlus | SURGERY | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordAuthor | Crohn&apos | - |
dc.subject.keywordAuthor | s disease | - |
dc.subject.keywordAuthor | CT-P13 | - |
dc.subject.keywordAuthor | pharmacokinetics | - |
dc.subject.keywordAuthor | ulcerative colitis | - |
dc.identifier.url | https://journals.lww.com/jcge/Fulltext/9900/Comparison_of_the_Pharmacokinetics_of_CT_P13.20.aspx | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.